Targeting tumour immunosuppressive microenvironment is a crucial strategy in
immunotherapy. However, the critical role of the tumour lymph node (LN) immune …

T-cell based immune response can attack cancer cells formidably when certain immune
checkpoint (eg, PD-1/PD-L1) is blocked. Unfortunately, PD-1/PD-L1 blockade only provoke …

Despite their immense therapeutic potential, cancer immunotherapies such as immune
checkpoint blockers (ICBs) benefit only a small subset of patients. Toll-like receptor agonists …

Immunotherapy that activates immune systems for combating cancer has yielded
considerable clinical benefits recently. However, the immunosuppressive tumor …

Immunological tolerance of tumors is characterized by insufficient infiltration of cytotoxic T
lymphocytes (CTLs) and immunosuppressive microenvironment of tumor. Tumor resistance …

Ovarian cancer is especially deadly, challenging to treat, and has proven refractory to known
immunotherapies. Cytokine therapy is an attractive strategy to drive a proinflammatory …

Current cancer immunotherapy has limited response rates in a large variety of solid tumors
partly due to the low immunogenicity of the tumor cells and the immunosuppressive tumor …

Cancer immunotherapy, a promising and widely applied mode of oncotherapy, makes use of
immune stimulants and modulators to overcome the immune dysregulation present in …

The immunosuppressive tumor microenvironment (TME) greatly limits the actual outcome of
immunotherapy. Therefore, it is urgent to develop appropriate strategies to reshape the TME …

Cancer immunotherapy that deploys the host's immune system to recognize and attack
tumors, is a promising strategy for cancer treatment. However, its efficacy is greatly restricted …